GENEVA/ZURICH, (Reuters) - Health officials reviewing Gilead Science Inc’s remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said yesterday.
The article WHO: Nations mulling Gilead’s COVID drug should consider trial flop, too appeared first on Stabroek News.
